GB0018891D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0018891D0
GB0018891D0 GBGB0018891.2A GB0018891A GB0018891D0 GB 0018891 D0 GB0018891 D0 GB 0018891D0 GB 0018891 A GB0018891 A GB 0018891A GB 0018891 D0 GB0018891 D0 GB 0018891D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0018891.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9896782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0018891(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0018891.2A priority Critical patent/GB0018891D0/en
Publication of GB0018891D0 publication Critical patent/GB0018891D0/en
Priority to TW090118314A priority patent/TWI282341B/zh
Priority to PE2001000760A priority patent/PE20020176A1/es
Priority to US10/343,288 priority patent/US7473761B2/en
Priority to IL15392001A priority patent/IL153920A0/xx
Priority to EP01969555A priority patent/EP1307486B1/en
Priority to KR10-2003-7001435A priority patent/KR20030033008A/ko
Priority to CZ20030288A priority patent/CZ302461B6/cs
Priority to HK03108087.4A priority patent/HK1057051B/en
Priority to PL358718A priority patent/PL204161B1/pl
Priority to KR1020067005526A priority patent/KR100799394B1/ko
Priority to DE60133823T priority patent/DE60133823T2/de
Priority to DK01969555T priority patent/DK1307486T3/da
Priority to SI200130836T priority patent/SI1307486T1/sl
Priority to ES01969555T priority patent/ES2305104T3/es
Priority to AU2001289778A priority patent/AU2001289778B2/en
Priority to NZ523836A priority patent/NZ523836A/en
Priority to BRPI0112859A priority patent/BRPI0112859B8/pt
Priority to JP2002515921A priority patent/JP3829118B2/ja
Priority to CNB018136869A priority patent/CN1267451C/zh
Priority to PCT/EP2001/008824 priority patent/WO2002010192A2/en
Priority to HU0300684A priority patent/HU227812B1/hu
Priority to SK121-2003A priority patent/SK287798B6/sk
Priority to PT01969555T priority patent/PT1307486E/pt
Priority to CA2416293A priority patent/CA2416293C/en
Priority to AT01969555T priority patent/ATE393782T1/de
Priority to RU2003105817/04A priority patent/RU2287533C2/ru
Priority to MYPI20013578A priority patent/MY138074A/en
Priority to MXPA03000991A priority patent/MXPA03000991A/es
Priority to ARP010103642A priority patent/AR034132A1/es
Priority to AU8977801A priority patent/AU8977801A/xx
Priority to IL153920A priority patent/IL153920A/en
Priority to ZA200300406A priority patent/ZA200300406B/xx
Priority to EC2003004456A priority patent/ECSP034456A/es
Priority to NO20030484A priority patent/NO331093B1/no
Priority to CY20081100789T priority patent/CY1108547T1/el
Priority to US12/265,135 priority patent/US7939625B2/en
Priority to US13/048,932 priority patent/US8822637B2/en
Priority to US13/048,935 priority patent/US9035021B2/en
Priority to LU92024C priority patent/LU92024I2/fr
Priority to BE2012C026C priority patent/BE2012C026I2/fr
Priority to FR12C0041C priority patent/FR12C0041I2/fr
Priority to CY2012018C priority patent/CY2012018I1/el
Priority to NO2012012C priority patent/NO2012012I2/no
Priority to US14/681,226 priority patent/US20150218223A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
GBGB0018891.2A 2000-01-08 2000-08-01 Organic compounds Ceased GB0018891D0 (en)

Priority Applications (45)

Application Number Priority Date Filing Date Title
GBGB0018891.2A GB0018891D0 (en) 2000-08-01 2000-08-01 Organic compounds
TW090118314A TWI282341B (en) 2000-08-01 2001-07-26 Somatostatin analogues
PE2001000760A PE20020176A1 (es) 2000-08-01 2001-07-26 Analogos de somatostatina
ARP010103642A AR034132A1 (es) 2000-08-01 2001-07-30 Analogos de somatostatina, un proceso para su produccion y composicion farmaceutica
AU8977801A AU8977801A (en) 2000-08-01 2001-07-30 Somatostatin analogues
HU0300684A HU227812B1 (hu) 2000-08-01 2001-07-30 Szomatosztatin analógok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
CA2416293A CA2416293C (en) 2000-08-01 2001-07-30 Somatostatin analogues
EP01969555A EP1307486B1 (en) 2000-08-01 2001-07-30 Somatostatin analogues
KR10-2003-7001435A KR20030033008A (ko) 2000-08-01 2001-07-30 소마토스타틴 유사체
CZ20030288A CZ302461B6 (cs) 2000-08-01 2001-07-30 Cyklický hexapeptid, zpusob jeho výroby, farmaceutický prípravek tento cyklický hexapeptid obsahující a použití tohoto cyklického hexapeptidu pro výrobu léciva
HK03108087.4A HK1057051B (en) 2000-08-01 2001-07-30 Somatostatin analogues
PL358718A PL204161B1 (pl) 2000-08-01 2001-07-30 Cykloheksapeptydowe analogi somatostatyny, sposób ich otrzymywania, kompozycje farmaceutyczne zawierające te związki oraz zastosowanie tych związków
KR1020067005526A KR100799394B1 (ko) 2000-08-01 2001-07-30 소마토스타틴 유사체
DE60133823T DE60133823T2 (de) 2000-08-01 2001-07-30 Somatostatin analoge verbindungen
DK01969555T DK1307486T3 (da) 2000-08-01 2001-07-30 Somatostatinanaloger
SI200130836T SI1307486T1 (sl) 2000-08-01 2001-07-30 Somatostatinski analogi
ES01969555T ES2305104T3 (es) 2000-08-01 2001-07-30 Analogos de somatostatina.
AU2001289778A AU2001289778B2 (en) 2000-08-01 2001-07-30 Somatostatin analogues
NZ523836A NZ523836A (en) 2000-08-01 2001-07-30 Somatostatin analogues
BRPI0112859A BRPI0112859B8 (pt) 2000-08-01 2001-07-30 análogos de somatostatina, composição farmacêutica, bem como uso dos referidos análogos
JP2002515921A JP3829118B2 (ja) 2000-08-01 2001-07-30 ソマトスタチンアナログ
CNB018136869A CN1267451C (zh) 2000-08-01 2001-07-30 促生长素抑制素类似物
PCT/EP2001/008824 WO2002010192A2 (en) 2000-08-01 2001-07-30 Somatostatin analogues
US10/343,288 US7473761B2 (en) 2000-08-01 2001-07-30 Somatostatin analogues
SK121-2003A SK287798B6 (sk) 2000-08-01 2001-07-30 Analógy somatostatínu, spôsob ich prípravy a farmaceutické kompozície, ktoré tieto analógy obsahujú, a ich použitie
PT01969555T PT1307486E (pt) 2000-08-01 2001-07-30 Análogos de somatostatina
IL15392001A IL153920A0 (en) 2000-08-01 2001-07-30 Somatostatin analogues
AT01969555T ATE393782T1 (de) 2000-08-01 2001-07-30 Somatostatin analoge verbindungen
RU2003105817/04A RU2287533C2 (ru) 2000-08-01 2001-07-30 Аналоги соматостатина
MYPI20013578A MY138074A (en) 2000-08-01 2001-07-30 Somatostatin analogues
MXPA03000991A MXPA03000991A (es) 2000-08-01 2001-07-30 Analogos de somatostatina.
IL153920A IL153920A (en) 2000-08-01 2003-01-13 Somatostatin analogues, processes for their production, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for therapy
ZA200300406A ZA200300406B (en) 2000-08-01 2003-01-15 Somatostatin analogues.
EC2003004456A ECSP034456A (es) 2000-08-01 2003-01-29 Analogos de somatostatina
NO20030484A NO331093B1 (no) 2000-08-01 2003-01-30 Somatostatinanaloger, fremgangsmåte for fremstilling, farmasøytisk sammensetning og anvendelse derav.
CY20081100789T CY1108547T1 (el) 2000-08-01 2008-07-29 Αναλογα σωματοστατινης
US12/265,135 US7939625B2 (en) 2000-08-01 2008-11-05 Somatostatin analogues
US13/048,932 US8822637B2 (en) 2000-08-01 2011-03-16 Somatostatin analogues
US13/048,935 US9035021B2 (en) 2000-08-01 2011-03-16 Somatostatin analogues
LU92024C LU92024I2 (fr) 2000-08-01 2012-06-20 Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
BE2012C026C BE2012C026I2 (https=) 2000-08-01 2012-06-21
FR12C0041C FR12C0041I2 (fr) 2000-08-01 2012-06-26 Analogues de somatostatine
CY2012018C CY2012018I1 (el) 2000-08-01 2012-06-29 Αναλογα σωματοστατινης
NO2012012C NO2012012I2 (no) 2000-08-01 2012-06-29 Pasireotide (som diaspartat salt). Det kjemiske navnet er cyclo[(4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L-phenylalanyl-)
US14/681,226 US20150218223A1 (en) 2000-01-08 2015-04-08 Somatostatin Analogues

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0018891.2A GB0018891D0 (en) 2000-08-01 2000-08-01 Organic compounds

Publications (1)

Publication Number Publication Date
GB0018891D0 true GB0018891D0 (en) 2000-09-20

Family

ID=9896782

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0018891.2A Ceased GB0018891D0 (en) 2000-01-08 2000-08-01 Organic compounds

Country Status (35)

Country Link
US (5) US7473761B2 (https=)
EP (1) EP1307486B1 (https=)
JP (1) JP3829118B2 (https=)
KR (2) KR20030033008A (https=)
CN (1) CN1267451C (https=)
AR (1) AR034132A1 (https=)
AT (1) ATE393782T1 (https=)
AU (2) AU2001289778B2 (https=)
BE (1) BE2012C026I2 (https=)
BR (1) BRPI0112859B8 (https=)
CA (1) CA2416293C (https=)
CY (2) CY1108547T1 (https=)
CZ (1) CZ302461B6 (https=)
DE (1) DE60133823T2 (https=)
DK (1) DK1307486T3 (https=)
EC (1) ECSP034456A (https=)
ES (1) ES2305104T3 (https=)
FR (1) FR12C0041I2 (https=)
GB (1) GB0018891D0 (https=)
HU (1) HU227812B1 (https=)
IL (2) IL153920A0 (https=)
LU (1) LU92024I2 (https=)
MX (1) MXPA03000991A (https=)
MY (1) MY138074A (https=)
NO (2) NO331093B1 (https=)
NZ (1) NZ523836A (https=)
PE (1) PE20020176A1 (https=)
PL (1) PL204161B1 (https=)
PT (1) PT1307486E (https=)
RU (1) RU2287533C2 (https=)
SI (1) SI1307486T1 (https=)
SK (1) SK287798B6 (https=)
TW (1) TWI282341B (https=)
WO (1) WO2002010192A2 (https=)
ZA (1) ZA200300406B (https=)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7189856B2 (en) 2001-12-28 2007-03-13 Gideon Shapiro Non-peptide somatostatin receptor ligands
ATE461173T1 (de) * 2002-12-12 2010-04-15 Novartis Pharma Gmbh Prozess für die herstellung von peptiden, die eine 4-hydorxy-prolin substruktur enthalten
GB0229020D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic compounds
GB0300095D0 (en) * 2003-01-03 2003-02-05 Novartis Ag Organic compounds
GB0314695D0 (en) * 2003-06-24 2003-07-30 Novartis Ag Organic compounds
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
GB0318682D0 (en) * 2003-08-08 2003-09-10 Novartis Ag Organic compounds
EP1522311A1 (fr) 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
GB0412866D0 (en) * 2004-06-09 2004-07-14 Novartis Ag Organic compounds
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
KR20090019896A (ko) * 2006-06-08 2009-02-25 노파르티스 아게 도파민 또는 성장 호르몬 수용체 길항제와의 소마토스타틴-유사체의 조합물
US7697338B2 (en) * 2006-11-16 2010-04-13 Sandisk Corporation Systems for controlled boosting in non-volatile memory soft programming
CN101553728B (zh) * 2006-11-28 2013-02-06 香港大学 颗粒体蛋白-上皮素前体(gep)抗体用于检测和抑制肝细胞癌(hcc)的用途
EP1941902A1 (en) * 2007-01-02 2008-07-09 Novartis AG Use of Somatostatin analogs in cluster headache
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
PE20090387A1 (es) 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
WO2009009035A1 (en) * 2007-07-06 2009-01-15 Ipsen Pharma S.A.S. Somatostatin analog and uses thereof
GB0719818D0 (en) * 2007-10-11 2007-11-21 Asterion Ltd Growth hormone fusion polypeptides
ES2536778T3 (es) * 2007-11-28 2015-05-28 Novartis Ag Uso de análogos de somatostatina en meningioma
EP2067786A1 (en) 2007-12-07 2009-06-10 ITALFARMACO S.p.A. Novel non selective analogs of somatostatin
US8937152B2 (en) * 2007-12-03 2015-01-20 Italfarmaco Spa Non-selective somatostatin analogues
US20090325863A1 (en) * 2008-06-13 2009-12-31 Kleinberg David L Somatostatin analogs and IGF-I inhibition for breast cancer prevention
WO2010003939A1 (en) 2008-07-08 2010-01-14 Novartis Ag Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia
EP2172189A1 (en) 2008-10-01 2010-04-07 Novartis AG Pharmaceutical Compositions
EP2213307A1 (en) 2009-02-03 2010-08-04 Novartis AG Injectable depot formulations
KR101814186B1 (ko) 2008-09-17 2018-03-14 키아스마 인코포레이티드 약제학적 조성물 및 연관된 투여방법
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
US8629103B2 (en) 2010-12-02 2014-01-14 New York University Treatment of non-proliferative cystic disease of the breast
EP2651917A1 (en) 2010-12-13 2013-10-23 Novartis AG Dimeric iap inhibitors
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
US20130035054A1 (en) * 2011-07-14 2013-02-07 Faceon Mobile Phone with multi-portal access for display during incoming and outgoing call
WO2013019923A2 (en) 2011-08-02 2013-02-07 New York University Methods for detecting progenitor cells and uses thereof
BR112014007310A2 (pt) 2011-09-27 2017-04-04 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
EP2788330A1 (en) 2011-12-05 2014-10-15 Novartis AG Cyclic urea derivatives as androgen receptor antagonists
MX350929B (es) 2011-12-05 2017-09-26 Camurus Ab Formulaciones peptidicas robustas de liberación controlada.
EP2802658A2 (en) 2012-01-09 2014-11-19 Novartis AG Rnai agents to treat beta-catenin related diseases
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
BR112014029425A2 (pt) * 2012-05-25 2017-06-27 Camurus Ab pré-formulação, dispositivo de administração pré-cheio, kit, processo para a formação de uma pré-formulação, usos de mistura e de um solvente polar, e, método para o tratamento de um sujeito
TWI704919B (zh) 2012-05-31 2020-09-21 日商大塚製藥股份有限公司 用於預防及/或治療多囊性腎臟病之藥物
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US9480759B2 (en) 2012-11-21 2016-11-01 Serene, Llc Tin-117m somatostatin receptor binding compounds and methods
ES2671516T3 (es) 2013-02-19 2018-06-06 Novartis Ag Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
AU2014229283B2 (en) 2013-03-14 2016-07-28 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
WO2014147586A1 (en) 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
CN103467575B (zh) * 2013-08-22 2016-03-02 深圳翰宇药业股份有限公司 一种帕西瑞肽的制备方法
CN103641894B (zh) * 2013-12-06 2015-10-28 深圳翰宇药业股份有限公司 一种治疗库欣病的多肽药物的制备方法
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
EP3082765B1 (en) 2013-12-19 2018-08-01 Novartis AG Drug delivery systems
WO2015107494A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
KR20170005492A (ko) 2014-05-28 2017-01-13 아이데닉스 파마슈티칼스 엘엘씨 암의 치료를 위한 뉴클레오시드 유도체
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
US10508108B2 (en) 2014-12-05 2019-12-17 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
US10086000B2 (en) 2014-12-05 2018-10-02 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
EP3226688B1 (en) 2014-12-05 2020-07-01 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant idh enzymes
AU2015360485B2 (en) 2014-12-10 2020-06-25 Amryt Endo, Inc. Oral octreotide administered in combination with other therapeutic agents
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
WO2016097962A1 (en) * 2014-12-19 2016-06-23 Auro Peptides Ltd A process for the preparation of pasireotide
WO2016126830A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2016162127A1 (en) * 2015-04-08 2016-10-13 Polyphor Ag Backbone-cyclized peptidomimetics
US10815264B2 (en) 2015-05-27 2020-10-27 Southern Research Institute Nucleotides for the treatment of cancer
US10287266B2 (en) 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
EP3310779B1 (en) 2015-06-19 2019-05-08 Novartis AG Compounds and compositions for inhibiting the activity of shp2
WO2016207912A1 (en) * 2015-06-22 2016-12-29 Biophore India Pharmaceuticals Pvt. Ltd. Novel process for the preparation of pasireotide
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
KR102222186B1 (ko) 2015-08-13 2021-03-03 머크 샤프 앤드 돔 코포레이션 Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
WO2017106062A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Novel compounds as indoleamine 2,3-dioxygenase inhibitors
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
DK3452465T3 (da) 2016-05-04 2021-02-08 Genoscience Pharma Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
WO2017216706A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
PT3523287T (pt) 2016-10-04 2021-10-06 Merck Sharp & Dohme Compostos de benzo[b]tiofeno como agonistas de sting
US20190365788A1 (en) 2016-11-21 2019-12-05 Idenix Pharmaceuticals Llc Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
CN110234403A (zh) 2017-01-27 2019-09-13 詹森生物科技公司 作为sting激动剂的环状二核苷酸
US11021511B2 (en) 2017-01-27 2021-06-01 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
RU2020109328A (ru) 2017-08-04 2021-09-06 Мерк Шарп И Доум Корп. Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака
JP2020530838A (ja) 2017-08-04 2020-10-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
JP7447002B2 (ja) 2017-09-11 2024-03-11 クルーゾン・ファーマシューティカルズ・インコーポレイテッド ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤
WO2019067332A1 (en) 2017-09-27 2019-04-04 Merck Sharp & Dohme Corp. COMPOSITIONS AND METHODS FOR TREATING CANCER THROUGH A COMBINATION OF PROGRAMMED DEATH ANTIBODY ANTIBODIES (PD-1) AND A CXCR2 ANTAGONIST
WO2019078968A2 (en) * 2017-10-18 2019-04-25 Angex Pharmaceutical, Inc. CYCLIC COMPOUNDS AS IMMUNOMODULATORS
WO2019089412A1 (en) 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
WO2019099294A1 (en) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
KR102718287B1 (ko) 2017-11-14 2024-10-16 머크 샤프 앤드 돔 엘엘씨 인돌아민 2,3-디옥시게나제 (ido) 억제제로서의 신규 치환된 비아릴 화합물
CN111712509A (zh) 2017-12-15 2020-09-25 詹森生物科技公司 作为sting激动剂的环状二核苷酸
EP3727401A4 (en) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EP3765006A4 (en) 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
EP3774765A4 (en) 2018-04-03 2021-12-29 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
JP7326319B2 (ja) 2018-04-03 2023-08-15 メルク・シャープ・アンド・ドーム・エルエルシー Ｓｔｉｎｇアゴニストとしてのベンゾチオフェン類及び関連する化合物
EP3781687A4 (en) 2018-04-20 2022-02-09 Merck Sharp & Dohme Corp. NEW RIG-I SUBSTITUTED AGONISTS: COMPOSITIONS AND METHODS THEREOF
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019231870A1 (en) 2018-05-31 2019-12-05 Merck Sharp & Dohme Corp. Novel substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
WO2019245890A1 (en) 2018-06-20 2019-12-26 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
CR20210175A (es) 2018-09-18 2021-06-01 Nikang Therapeutics Inc Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2)
JP2022502495A (ja) 2018-09-25 2022-01-11 ブラック ダイアモンド セラピューティクス，インコーポレイティド チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用
US20220041613A1 (en) 2018-09-25 2022-02-10 Black Diamond Therapeutics, Inc. Tyrosine kinase inhibitor compositions, methods of making and methods of use
IL305106B2 (en) 2018-09-29 2025-08-01 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2
EP3873464B1 (en) 2018-11-01 2025-07-30 Merck Sharp & Dohme LLC Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
WO2020096871A1 (en) 2018-11-06 2020-05-14 Merck Sharp & Dohme Corp. Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors
EP3886845B1 (en) 2018-11-28 2024-09-04 Merck Sharp & Dohme LLC Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors
EP3897622B1 (en) 2018-12-18 2026-01-14 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use
WO2020205688A1 (en) 2019-04-04 2020-10-08 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
EP3990635A1 (en) 2019-06-27 2022-05-04 Rigontec GmbH Design method for optimized rig-i ligands
JP7843695B2 (ja) 2019-08-02 2026-04-10 メルサナ セラピューティクス インコーポレイテッド がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物
AU2020328598A1 (en) 2019-08-15 2022-03-03 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
WO2021083060A1 (zh) 2019-10-28 2021-05-06 中国科学院上海药物研究所 五元杂环氧代羧酸类化合物及其医药用途
EP4069683A1 (en) 2019-12-06 2022-10-12 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
US20220396577A1 (en) 2019-12-17 2022-12-15 Merck Sharp & Dohme Llc Novel substituted 1,3-8-triazaspiro[4,5] decane-2,4-dione compounds as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors
EP4087583B1 (en) 2020-01-07 2026-04-22 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use
WO2021195206A1 (en) 2020-03-24 2021-09-30 Black Diamond Therapeutics, Inc. Polymorphic forms and related uses
IL296901A (en) 2020-04-02 2022-12-01 Mersana Therapeutics Inc Antibody-drug conjugates comprising sting agonists
CR20220565A (es) 2020-05-06 2023-01-13 Merck Sharp & Dohme Llc Inhibidores de il4i1 y métodos de uso
WO2022140472A1 (en) 2020-12-22 2022-06-30 Nikang Therapeutics, Inc. Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
AU2022207648A1 (en) 2021-01-13 2023-07-27 Monte Rosa Therapeutics Ag Isoindolinone compounds
WO2022170052A1 (en) 2021-02-05 2022-08-11 Black Diamond Therapeutics, Inc. Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
WO2022219412A1 (en) 2021-04-14 2022-10-20 Monte Rosa Therapeutics Ag Isoindolinone amide compounds useful to treat diseases associated with gspt1
EP4323350A1 (en) 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Isoindolinone compounds
WO2022227015A1 (en) 2021-04-30 2022-11-03 Merck Sharp & Dohme Corp. Il4i1 inhibitors and methods of use
TW202317589A (zh) 2021-07-14 2023-05-01 美商尼坎醫療公司 作為ｋｒａｓ抑制劑的伸烷基衍生物
CN119053595A (zh) 2022-03-28 2024-11-29 尼坎治疗公司 作为细胞周期蛋白依赖性激酶2抑制剂的磺酰氨基衍生物
CN119790053A (zh) 2022-06-08 2025-04-08 霖康疗法公司 作为细胞周期蛋白依赖性激酶2抑制剂的磺酰胺衍生物
JP2025528439A (ja) * 2022-08-30 2025-08-28 グラフトン セラピューティクス エスアエールエル 複数のソマトスタチン受容体サブタイプ選択性を有するハロゲン化ソマトスタチン類似体
AU2023375457A1 (en) 2022-11-11 2025-05-01 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
AR132248A1 (es) 2023-03-29 2025-06-11 Merck Sharp & Dohme Llc Inhibidores de il4i1 y métodos para su uso
CN121443321A (zh) 2023-06-30 2026-01-30 默沙东有限责任公司 治疗组合及其用途和治疗方法
WO2025072462A1 (en) 2023-09-27 2025-04-03 Nikang Therapeutics, Inc. Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
TW202527955A (zh) 2023-11-27 2025-07-16 美商尼坎醫療公司 用於經由泛素蛋白酶體途徑降解週期蛋白依賴性激酶２和週期蛋白依賴性激酶４的含有２，５－取代的嘧啶衍生物的雙功能化合物
WO2025117981A1 (en) 2023-12-02 2025-06-05 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
WO2025212828A1 (en) 2024-04-03 2025-10-09 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
WO2025240536A1 (en) 2024-05-15 2025-11-20 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3863008A (en) 1973-06-11 1975-01-28 American Home Prod Somatostatin as stimulant of luteinizing hormone secretion
NZ195303A (en) 1979-10-31 1984-10-19 Merck & Co Inc Cyclic hexapeptide somatostatin analogues,and pharmaceutical compositions
US4292972A (en) 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
US4612386A (en) * 1980-09-16 1986-09-16 The Dow Chemical Company Process for making esters
US4505897A (en) 1983-04-18 1985-03-19 The Administrators Of The Tulane Educational Fund Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith
US4612366A (en) 1985-06-17 1986-09-16 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
CA2012115C (en) 1989-03-15 2001-07-03 Biomeasure, Inc. Iodinated somatostatins
CA2053250A1 (en) 1989-04-26 1990-10-27 David H. Coy Linear somatostatin analogs
DK0720621T3 (da) 1992-01-14 2001-08-06 Diatide Inc Radiomærkede somatostation-afledte peptider til billeddannende og terapeutiske anvendelser
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
RO117259B1 (ro) 1993-08-09 2001-12-28 Biomeasure Inc. Derivaţi peptidici, terapeutici
US5770687A (en) 1995-06-07 1998-06-23 Peptor Limited Comformationally constrained backbone cyclized somatostatin analogs
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB9513224D0 (en) * 1995-06-29 1995-09-06 Sandoz Ltd Organic compounds
IT1277391B1 (it) 1995-07-28 1997-11-10 Romano Deghenghi Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
WO1997043278A1 (en) 1996-05-14 1997-11-20 Novo Nordisk A/S Somatostatin agonists and antagonists
US6355613B1 (en) 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
CA2246791A1 (en) 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
BE2012C026I2 (https=) 2020-12-15
CZ302461B6 (cs) 2011-06-01
FR12C0041I1 (https=) 2012-07-27
US7473761B2 (en) 2009-01-06
SK287798B6 (sk) 2011-10-04
AR034132A1 (es) 2004-02-04
TWI282341B (en) 2007-06-11
CZ2003288A3 (cs) 2003-05-14
US20050014686A1 (en) 2005-01-20
ES2305104T3 (es) 2008-11-01
KR100799394B1 (ko) 2008-01-30
NO20030484D0 (no) 2003-01-30
US8822637B2 (en) 2014-09-02
PL204161B1 (pl) 2009-12-31
JP3829118B2 (ja) 2006-10-04
RU2287533C2 (ru) 2006-11-20
KR20060035809A (ko) 2006-04-26
NO2012012I2 (no) 2012-07-30
DK1307486T3 (da) 2008-08-25
BR0112859A (pt) 2003-07-01
CY2012018I2 (el) 2015-10-07
PE20020176A1 (es) 2002-03-26
ZA200300406B (en) 2004-04-02
CY2012018I1 (el) 2015-10-07
HK1057051A1 (en) 2004-03-12
PT1307486E (pt) 2008-07-31
US20110172157A1 (en) 2011-07-14
NO2012012I1 (no) 2012-06-29
HU227812B1 (hu) 2012-03-28
MY138074A (en) 2009-04-30
EP1307486A2 (en) 2003-05-07
NO331093B1 (no) 2011-10-03
AU8977801A (en) 2002-02-13
CY1108547T1 (el) 2014-04-09
US7939625B2 (en) 2011-05-10
SI1307486T1 (sl) 2008-08-31
IL153920A0 (en) 2003-07-31
HUP0300684A3 (en) 2004-08-30
HUP0300684A2 (hu) 2003-09-29
NO20030484L (no) 2003-03-19
CA2416293A1 (en) 2002-02-07
DE60133823D1 (de) 2008-06-12
US20090069225A1 (en) 2009-03-12
CN1446229A (zh) 2003-10-01
EP1307486B1 (en) 2008-04-30
US9035021B2 (en) 2015-05-19
CN1267451C (zh) 2006-08-02
JP2004505095A (ja) 2004-02-19
DE60133823T2 (de) 2009-05-20
NZ523836A (en) 2004-08-27
PL358718A1 (en) 2004-08-09
WO2002010192A9 (en) 2002-10-17
CA2416293C (en) 2011-05-10
IL153920A (en) 2010-12-30
WO2002010192A3 (en) 2002-09-19
FR12C0041I2 (fr) 2013-01-11
WO2002010192A2 (en) 2002-02-07
ATE393782T1 (de) 2008-05-15
US20150218223A1 (en) 2015-08-06
MXPA03000991A (es) 2003-06-09
BRPI0112859B8 (pt) 2021-05-25
AU2001289778B2 (en) 2005-02-03
US20110166320A1 (en) 2011-07-07
LU92024I2 (fr) 2012-08-20
SK1212003A3 (en) 2003-08-05
BRPI0112859B1 (pt) 2016-03-01
KR20030033008A (ko) 2003-04-26
ECSP034456A (es) 2003-03-10

Similar Documents

Publication Publication Date Title
AU8389101A (en) Organic compounds
GB0010955D0 (en) Organic compounds
GB0006398D0 (en) Organic compounds
GB0001448D0 (en) Organic compounds
GB0003111D0 (en) Organic compounds
GB0008694D0 (en) Organic compounds
GB0008785D0 (en) Organic compounds
GB0002100D0 (en) Organic compounds
AU3458802A (en) Organic compounds
GB0007108D0 (en) Organic compounds
GB0007911D0 (en) Organic compounds
GB0002740D0 (en) Organic compounds
GB0009037D0 (en) Organic compounds
GB0009054D0 (en) Organic compounds
GB0009053D0 (en) Organic compounds
GB0009055D0 (en) Organic compounds
GB0010200D0 (en) Organic compounds
GB0002180D0 (en) Organic compounds
GB0022439D0 (en) Organic compounds
GB0010486D0 (en) Organic compounds
GB0010484D0 (en) Organic compounds
GB0010483D0 (en) Organic compounds
GB0010211D0 (en) Organic compounds
GB0010210D0 (en) Organic compounds
GB0010208D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)